Prognostic Value of CD1B in Localised Prostate Cancer

Int J Environ Res Public Health. 2019 Nov 27;16(23):4723. doi: 10.3390/ijerph16234723.

Authors

Cheng-Hsueh Lee^{1

2}, Lih-Chyang Chen³, Chia-Cheng Yu^{4

5

6}, Wen-Hsin Lin⁷, Victor C Lin^{8

9}, Chao-Yuan Huang¹⁰, Te-Ling Lu⁷, Shu-Pin Huang^{1

2

11

12}, Bo-Ying Bao^{7

13

14}

Affiliations

¹ Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan.
² Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
³ Department of Medicine, Mackay Medical College, New Taipei City 252, Taiwan.
⁴ Division of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan.
⁵ Department of Urology, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan.
⁶ Department of Pharmacy, Tajen University, Pingtung 907, Taiwan.
⁷ Department of Pharmacy, China Medical University, Taichung 404, Taiwan.
⁸ Department of Urology, E-Da Hospital, Kaohsiung 824, Taiwan.
⁹ School of Medicine for International Students, I-Shou University, Kaohsiung 840, Taiwan.
¹⁰ Department of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei 100, Taiwan.
¹¹ Department of Urology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
¹² Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung 804, Taiwan.
¹³ Sex Hormone Research Center, China Medical University Hospital, Taichung 404, Taiwan.
¹⁴ Department of Nursing, Asia University, Taichung 413, Taiwan.

Abstract

Cluster of differentiation (CD) antigens are cell surface markers used to differentiate haematopoietic cell types. These antigens are present in various malignancies and are reportedly linked to patient prognosis; however, they have not been implemented as prostate cancer progression markers. Here, we aimed to assess the impact of genetic variation in haematopoietic cell CD markers on clinical outcomes in patients with prostate cancer. An association study of 458 patients with prostate cancer was conducted to identify single-nucleotide polymorphisms in 11 candidate CD marker genes associated with biochemical recurrence (BCR) after radical prostatectomy. Identified predictors were further evaluated in an additional cohort of 185 patients. Joint population analyses showed that CD1B rs3181082 is associated with BCR (adjusted hazard ratio 1.42, 95% confidence interval 1.09-1.85, p = 0.010). In addition, rs3181082 overlapped with predicted transcriptional regulatory elements and affected CD1B expression. Furthermore, low CD1B expression correlated with poorer BCR-free survival. Our results indicated that CD1B rs3181082 confers prostate cancer progression and may help improve clinical prognostic stratification.

Keywords: CD antigen; CD1B; biomarker; prognosis; prostate cancer.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antigens, CD1 / metabolism*
Biomarkers, Tumor / metabolism
Humans
Male
Middle Aged
Polymorphism, Single Nucleotide
Predictive Value of Tests
Proportional Hazards Models
Prostatic Neoplasms / genetics
Prostatic Neoplasms / metabolism*

Substances

Antigens, CD1
Biomarkers, Tumor
CD1b antigen